A series of copper(II) and cobalt(II) coordination compounds with 2-substituted benzimidazole derived monodentate and bidentate ligands have been prepared and characterized by microanalysis, IR and UV-Vis spectroscopy. Synthesized metal complexes have been screened for their in vitro antioxidant and antitumor activity. The complex 4a showed significant nitric oxide free radical scavenging activity (IC 50 65µg/ml), while 3i and 3g showed potent superoxide dismutase activity with IC 50 of 0.26 and 0.28 µM respectively. In vitro cytotoxicity study with human breast MCF-7 and CNS SF 268 cancer cell lines showed that the most active 2benzyl-1H-benzimidazole Cu(II) complex 3a inhibited the growth of cancer cells at 20 µM concentration.
INTRODUCTION
2-Substituted benzimidazole derivatives are an important class of compounds in medicinal and organic chemistry. The benzimidazole moiety is a structural element of compounds with a wide range of biological activities [1] [2] [3] [4] . For example, 2-substituted benzimidazoles exhibit inhibitory activity against a range of human tumour cell lines in vitro. [5] [6] [7] In addition transition metal complexes of 2-substituted benzimidazole ligands act as anticancer agents [8] [9] [10] [11] [12] . Cancer cells are found to have less superoxide dismutase activity than normal cells 13, 14 and copper(II) complexes are known to mimic activity of copper, zinc-superoxide dismutase (Cu,Zn-SOD), an antioxidant enzyme that protect cells from the toxic effect of superoxide ion by its dismutation into dioxygen and hydrogen peroxide in biological systems 15 . The antitumor activity of SOD metal complexes has been suggested to be due to their superoxide scavenging ability 16 . Above observations prompted us to synthesize various 2-substituted benzimidazole-copper(II) and cobalt(II) complexes 3a-i and 4a-i as per Scheme 1 with a view to evaluate their anticancer and antioxidant activities.
MATERIALS AND METHODS
Melting points were obtained in an open capillary tube. Structures of all the compounds were confirmed by elemental analysis and spectral data. The IR spectra were recorded on Shimadzu 800 FTIR spectrometer in KBr pellets. The 1 H NMR spectra were recorded on a Perkin-Elmer R-32 (90 MHz) spectrometer in CDCl 3 using TMS as an internal standard. All chemical shift values are expressed in δ ppm. Mass spectra were recorded on a Shimadzu 2010A LC-MS spectrometer and UV spectra were taken on Perkin Elmer version 2.5 spectrophotometer. Elemental analysis of compounds was carried out on Flash EA 1112 series instrument. The homogeneity of all the compounds were verified on silica gel G coated TLC plates and the spots were located by iodine vapours. Chemistry. Synthesis of 2-substituted-1Hbenzimidazoles 1a-f was carried out according to the standard procedure 17 and characterization data is presented in Table 1 . 
Synthesis of 2-(alkyl/arylamine-1-ylmethyl)-1Hbenzimidazoles 2g-i:
To a mixture of 2-chloromethyl benzimidazole 1b (0.01mol) and appropriate amine (0.01 mol) in 50 ml of dry acetone, anhydrous potassium carbonate (0.69 g, 0.005 mol) was added. The reaction mixture was stirred at room temperature for 10-12 h. The solid thus obtained was filtered, washed with water, dried and recrystallized from acetone: methanol (1:1); 2g: IR (KBr, cm 
Synthesis of Dichlorobis[2-(alkyl/aryl/aralkyl/ thioaralkyl-1ylmethyl)-1H-benzimidazoles] copper (II) 3a-f:
Appropriate benzimidazole ligand 1a-f (0.01 mol) was dissolved in ethanol (50 ml) and the resulting solution was treated with copper(II) chloride (0.005 mol) dissolved in dimethylformamide (2 ml). The reaction mixture was stirred at room temperature for 6 h. The solid that separated in each case was filtered, washed with ether, dried and recrystallized from dimethylformamide UV-Vis absorption study. UV-Vis absorption study of complexes 3a and 4a at 4 µM concentration was carried out with respect to their corresponding ligands 1a and 4a, respectively in phosphate buffer saline solution (Dulbecco's buffer, pH 7.4), prewarmed at 37 0 C (Figure 1 and 2) . 10 µl of 20 mM DMF solution of the copper (3a) and cobalt (4a) complexes was added separately to Dulbecco's buffer (pH 7.4), pre-warmed at 37 0 C, resulting in a final concentration of 4 µM. Spectra at 0, 1, 2 and 3 h were recorded between 240 and 400 nm. The resulting stability profile is shown in figure 3 and 4. Biological evaluation. DPPH radical scavenging assay: Compounds 3a-i and 4a-i were evaluated as DPPH (1,1-diphenyl-2-picryl hydrazyl) free radical scavengers as described by Hwang et. al. 18 10 µl of the compound solution in a 1:1 DMSO/phosphate buffer (PH 7.4) mixture and 0.2 ml of DPPH in methanol solution was incubated at 37 0 C for 30 min and the absorbance of the supernatant was measured at 490 nm. IC 50 values were determined for the complexes 3a-i and 4a-i and the result is summarized with reference standard ascorbic acid in Table 2 .
Nitric oxide radical inhibition assay: Nitric oxide radical inhibition assay of compounds 3a-i and 4a-i was assayed 19 by incubating 2 ml sodium nitroprusside (10 mM), 0.5 phosphate buffer saline and 0.5 ml (0.25 mg) of compound solution in a 1:1 DMSO/phosphate buffer (PH 7.4) mixture at 25 0 C for 150 min. Then 1 ml of sulfanilic acid reagent was added to 0.5 ml of reaction mixture for 5 min to complete diazotization. Subsequently, 1 ml naphthyl ethylene diamine dihydrochloride (NEDD) was added and allowed to stand for 30 min at 25 0 C. The absorbance of these solutions was measured at 540 nm. IC 50 values were determined for the complexes 3a-i and 4a-i and the result is summarized with reference standard ascorbic acid in Table 2 .
Superoxide dismutase (SOD) activity: Super oxide dismutase (SOD) activity of complexes 3a-i and 4a-i was determined in a 96 well microtitre plate assay based on the ability of the complexes to inhibit the reduction of nitroblue tetrazolium salt (NBT) by superoxide ions, which are generated by the traditional xanthine/xanthine oxidase system 20 . Superoxide radical anions reduce NBT to a blue formazan, which was detected spectrophotometrically at 570 nm. Solutions of the synthesized compounds at four different concentrations were prepared in a 1:1 DMSO/phosphate buffer (PH 7.4) mixture and 10 µl were added to 8 wells per concentration to give a concentration range between 0.01 and 1µM. Atleast three independent assays were performed for each complex and IC 50 values were calculated for the complexes 3a-i and 4a-i and the result is summarized with reference standard rutin in Table 2 . In vitro antitumor activity: Antitumor activity of the newly synthesized compounds were evaluated by tryphan blue dye exclusion technique 21 against human breast MCF-7 and CNS SF 268 cancer cell lines at the concentration level of 20 µM. Each cell line is preincubated on microtitre plate, the test compounds are then added at 20 µM concentration. Cultures are incubated for fourty eight hours. Results for each compound are reported as the percent growth of the treated cells when compared to the untreated control cells. Primary screening of the compounds was done to indicate whether a compound possessed enough activity at this concentration to inhibit cell growth by 50 %. Results are given in Table 2 .
RESULTS AND DISCUSSION
The required starting material 2-substituted-1Hbenzimidazoles 1a-f was prepared 17 Metal complexes synthesized were characterized by IR, UV and elemental analysis. Elemental analysis suggested 1:2 (metal:ligand) stoichiometry for 3a-i and 4a-i and 1:1 (metal : ligand) stoichiometry for 3g-i and 4g-i complexes. IR spectrum of the complexes has shown some characteristic changes when compared to the free ligands. Ligands showed broad bands in the region 3460-3340 cm -1 due to the intermolecular hydrogen bonded imidazole N-H stretching. All the complexes which have free imidazole N-H, exhibited N-H stretching bands ranging from 3322 to 3140 cm -1 sharper than those of the ligands due to breaking of tautomerism, indicating that imidazole N-H was not involved in the coordination. Benzimidazole ligands exhibit strong to medium intensity bands in the region 1665-1630 cm -1 (C=N stretching), undergo a negative shift of 10-25 cm -1 which indicates involvement of azomethine nitrogen upon complexation. The other bands in the spectrum of each complex were similar to those in the corresponding ligand spectrum except for slight shifts in their positions and changes in their intensities due to coordination. Figure 1 and 2 presents representative UV-Vis spectra of two pairs of ligands and complexes. The absorptions in the UV region are comparable for both the ligands and complexes of copper(II) and cobalt(II). The absorptions of the copper(II) and cobalt(II) complexes, however, extend further out into the visible region >380 nm. Fig. 3 and 4 show the time-dependant changes in the UV-Vis spectra of the two of the complexes over 3 h when they were incubated at 37 0 C, in phosphate buffered saline. Compounds 3a and 4a showed a slow decrease in the intensity of the shape of the spectra over 3 h incubation but no change in the shape of the spectra and no crossing of the spectra was observed.
It is evident from result ( Table 2 ) that only Copper(II) complex 3a exhibited moderate (IC 50 51 µg/ml) DPPH free radical scavenging activity while all other compounds were found to be inactive (IC 50 >500 µg/ml) in comparison to the reference standard ascorbic acid (IC 50 41 µg/ml). In nitric oxide method compounds 3i and 4a showed significant free radical scavenging activity with an IC 50 of 76 µg/ml and 65 µg/ml, respectively in comparison to the reference standard rutin (IC 50 69 µg/ml). Compounds 3b, 3c, 3d, 3g and 4b exhibited moderate activity while all other compounds were found to be inactive and no correlation was observed between nitric oxide free radical scavenging activity, different substituents and Cu(II) and Co(II) complexes.
It is evident from superoxide dismutase activity result ( Table 2 ) that compounds 3f-i, 4a, 4c and 4e-g exhibited potent activity (IC 50 0.26-0.49 µM) while all other compounds were found to be moderately active in comparison to the reference standard rutin (IC 50 0.45 µM). Copper(II) complex 3i bearing morpholinomethyl group (IC 50 0.26 µM ) and co(II) complex 4g bearing piperidinomethyl group (IC 50 0.28 µM ) showed maximum superoxide dismutase activity.
As shown in Table 2 metal complexes 3a, 3c, 3f, 4b-d and 4g exhibited significant activity against human breast cancer MCF-7 cell line. Copper(II) complex bearing benzyl (3a) and cobalt(II) complexes bearing p-aminophenyl (4c) or piperidinomethyl (4g) substituents at position 2 of benzimidazole ring showed potent cytotoxicity against both human breast MCF 7 and human CNS SF 268 cancer cell lines while complexes 3c, 4b and 4d exhibited moderate cytotoxicity against human breast cancer cell lineMCF-7. As evident from result no correlation was observed between corresponding superoxide dismutase (SOD) IC 50 values and cytotoxic activity. This indicates that mechanisms other than SOD mimicking activity are responsible for their cytotoxic properties. Copper(II) complex 3i showed significant SOD mimicking activity but no cytotoxicity on MCF-7 and SF 268 cancer cell lines at 20 µM might be useful therapeutically as a SOD mimicking agent.
